Story perspectives

Johnson & Johnson Posts $24.6B Sales, Faces Investor Concerns

1/21/2026

Summary

Story summary

Johnson & Johnson reported fourth-quarter sales of $24.6 billion, up 9.1% on demand for new medicines despite Stelara's revenue decline.
The company forecast 2026 sales between $100 billion and $101 billion, modestly above expectations.
Joaquin Duato, Chief Executive Officer of Johnson & Johnson, highlighted growth in oncology and immunology.
But concerns remain about patent expirations and talcum powder-related litigation.
Shares fell 1% after results, signaling investor apprehension.

History

Historical Context

In 2006, Johnson & Johnson faced scrutiny when the FDA raised safety concerns about its products, undermining public trust. The company reported $63.5 billion in sales that year, showcasing its market strength. Today, despite a 9.1% sales increase to $24.6 billion, ongoing litigation and patent expirations echo past challenges, raising investor concerns about the company's future stability.

1 of 2

Story summary

Johnson & Johnson reported fourth-quarter sales of $24.6 billion, up 9.1% on demand for new medicines despite Stelara's revenue decline.
The company forecast 2026 sales between $100 billion and $101 billion, modestly above expectations.
Joaquin Duato, Chief Executive Officer of Johnson & Johnson, highlighted growth in oncology and immunology.
But concerns remain about patent expirations and talcum powder-related litigation.
Shares fell 1% after results, signaling investor apprehension.

1 / 2